ANAHEIM, CA—Dabigatran-based dual antithrombotic therapy maintains its advantage over warfarin-based triple therapy in terms of reducing bleeding in patients with A-fib undergoing PCI, a new analysis ...
NEW ORLEANS — New data from the AUGUSTUS trial provide insight on the appropriate antithrombotic regimen after ACS or PCI in patients with atrial fibrillation. Perspectives from Arnold Seto, MD, MPA; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback